Acute Altitude Illness and High-Altitude Cerebral Edema

Acute mountain sickness (AMS) is the common, usually self-limited syndrome of headache with associated symptoms that develops within hours of rapid ascent to high altitude, and high-altitude cerebral edema (HACE) is its severe, potentially fatal end of the spectrum, marked by ataxia and altered consciousness. Both reflect the brain's failure to adapt to hypobaric hypoxia, and they form a clinical continuum defined by rate of ascent, altitude reached, and individual susceptibility.

Definition

Acute mountain sickness is a self-reported syndrome of headache plus gastrointestinal, fatigue, or dizziness symptoms after recent ascent to altitude in an unacclimatized person, and high-altitude cerebral edema is the encephalopathy, characteristically with ataxia and impaired consciousness, that represents severe progression of the same process.

Scope

This topic covers the cerebral forms of altitude illness: the symptom complex of AMS, its scoring, and its progression to HACE. It addresses pathophysiology, recognized risk factors, and the concept of acclimatization that underlies prevention. It is framed as a reference account of how these conditions are defined and studied, not as clinical management guidance; high-altitude pulmonary edema is treated as a separate topic.

Core questions

• What distinguishes benign acclimatization from acute mountain sickness?
• How does AMS progress to high-altitude cerebral edema, and what marks that transition?
• Which ascent and host factors determine susceptibility?
• How is AMS severity defined and scored for research and field use?

Key concepts

• Hypobaric hypoxia
• Acclimatization
• Rate and altitude of ascent
• Lake Louise score
• Ataxia as a marker of HACE
• Vasogenic cerebral edema
• Individual susceptibility

Mechanisms

Ascent to high altitude lowers inspired oxygen partial pressure, producing hypobaric hypoxia to which the brain must adapt. AMS is thought to arise from the cerebral consequences of hypoxia, with proposed contributions from altered cerebral blood flow, mild brain swelling, and trigeminovascular activation producing headache, though the precise mechanism remains incompletely understood (Hackett & Roach, 2001; Basnyat & Murdoch, 2003). HACE represents progression to vasogenic cerebral edema with disruption of the blood-brain barrier and increased brain volume, clinically heralded by ataxia and declining consciousness as a continuum from severe AMS (Hackett & Roach, 2001). Acclimatization, the set of ventilatory and hematologic adaptations occurring over days, mitigates the hypoxic stress, which is why graded ascent is central to prevention (Basnyat & Murdoch, 2003; Luks et al., 2019).

Clinical relevance

AMS and HACE are leading reasons travelers seek care at altitude and are central to pre-travel counseling for trekkers and mountaineers, because recognition of the AMS-to-HACE continuum underlies safe ascent planning. This entry describes how the conditions are defined, scored, and conceptualized; it does not provide diagnostic thresholds, drug dosing, or individualized treatment advice.

Epidemiology

AMS is common among unacclimatized travelers who ascend rapidly above roughly moderate altitude, with frequency rising with higher altitude and faster ascent; HACE is uncommon but carries high risk if unrecognized (Hackett & Roach, 2001; Basnyat & Murdoch, 2003). Major determinants are the rate and absolute altitude of ascent and prior individual susceptibility, while a history of altitude illness predicts recurrence (Luks et al., 2019).

Evidence & guidelines

Severity is commonly characterized using the Lake Louise Acute Mountain Sickness Score, revised in 2018 to update the symptom items used in research and field assessment (Roach et al., 2018). The Wilderness Medical Society's 2019 clinical practice guidelines synthesize graded recommendations for the prevention and treatment of acute altitude illness, including AMS and HACE (Luks et al., 2019). Narrative reviews by Hackett and Roach (2001) and Basnyat and Murdoch (2003) remain widely cited syntheses of the pathophysiology and clinical spectrum.

History

Mountain sickness was described in early accounts of travel to high altitude, but systematic clinical characterization accompanied the post-war growth of recreational mountaineering. The recognition of HACE as the severe cerebral end of the AMS spectrum, and the development of standardized symptom scoring through the Lake Louise consensus, gave the field reproducible definitions; the 2018 revision of that score reflects continued refinement of how AMS is measured (Roach et al., 2018).

Debates

Should headache be a required symptom for diagnosing AMS?

The Lake Louise scoring framework centers on headache, and whether headache must be present for an AMS diagnosis has been debated in the development and revision of the consensus score.

Key figures

• Peter Hackett
• Robert Roach
• Buddha Basnyat
• Andrew Luks
• Peter Bärtsch

Seminal works

• hackett-roach-2001
• basnyat-murdoch-2003
• roach-2018

Frequently asked questions

What is the difference between acute mountain sickness and high-altitude cerebral edema?

Acute mountain sickness is the common, usually mild syndrome of headache and associated symptoms after rapid ascent, while high-altitude cerebral edema is its severe end of the spectrum, marked by ataxia and altered consciousness; the two are understood as a continuum rather than separate diseases.

Why does ascending slowly matter for altitude illness?

Graded ascent allows acclimatization, the physiological adaptation to lower oxygen that develops over days, so a slower rate and lower absolute altitude of ascent reduce the hypoxic stress that drives acute mountain sickness and its progression.